🔎 Trials Near Me

Почетна › Беркитов лимфом › Delaver

Kliničke studije za Беркитов лимфом u državi Delaver

7 studija za Беркитов лимфом traži učesnike na lokacijama u državi Delaver.

Zvanični tekst studije (na engleskom)

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Helen F Graham Cancer Center, Newark
  • Medical Oncology Hematology Consultants PA, Newark
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03739814

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Alfred I duPont Hospital for Children, Wilmington
Тражи се учесникФаза 2
Узраст од 1 до 30 · Оба пола · Ажурирано 12. 11. 2026. · NCT04546399

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Alfred I duPont Hospital for Children, Wilmington
Тражи се учесникФаза 2
365 Days · Оба пола · Ажурирано 27. 10. 2026. · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Alfred I duPont Hospital for Children, Wilmington
Тражи се учесникФаза 3
365 Days – 25 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT03959085

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Christiana Care Hospital - Helen F Graham Cancer Center, Newark
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 2. 2026. · NCT05544019

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • Alfred I. duPont Hospital for Children - Nemours Deleware, Wilmington
Тражи се учесникФаза 2
Узраст од 1 до 25 · Оба пола · Ажурирано 4. 5. 2025. · NCT03509961

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.